Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (GB:0JDI)
LSE:0JDI
Ionis Pharmaceuticals (0JDI) Share Price & Analysis
0 Followers
0JDI Stock Chart & Stats
Day’s Range$41.5 - $42.13
52-Week Range― - ―
Previous Close$41.86
Volume5.00
Average Volume (3M)N/A
Market Cap
$6.10B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 07, 2024EPS Estimate
-$1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$58.69Price Target Upside39.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Ionis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Market PotentialThe SHTG market is projected to perform better than the PCSK9 market, with expectations to surpass earlier sellside forecasts.
Product PipelineWith multiple products launching in 2024-2025, Ionis is anticipated to reach cash-flow positivity by 2027.
Stock UpgradeAnalyst upgrades Ionis to Outperform based on underappreciated revenue potential in SHTG.
Bears Say
Clinical Trial ConcernsInvestor confidence in TTR silencers was eroded after ALNY modified its HELIOS-B trial design.
Efficacy DoubtsThe change in the statistical analysis plan of a competitor's study suggests it was likely underpowered, adding uncertainty around the efficacy of the TTR silencer class.
Financial PerformanceSpinraza revenue was below analyst and consensus estimates, with Q4 Spinraza royalties missing the projected figures.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.88% Other Institutional Investors
98.12% Public Companies and
Individual Investors
0JDI FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Ionis Pharmaceuticals’s market cap?
Currently, no data Available
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is May 07, 2024 which is in 8 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Feb 21, 2024. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.804 by $0.744.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -$1.02.
How many shares outstanding does Ionis Pharmaceuticals have?
Currently, no data Available
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.804. Following the earnings report the stock price went down -1.65%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Among the largest hedge funds holding Ionis Pharmaceuticals’s share is Tweedy Browne CO LLC. It holds Ionis Pharmaceuticals’s shares valued at 175M.
---
Ionis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$58.69 (39.31% Upside)
$58.69 (39.31% Upside)
Blogger Sentiment
Bullish
GB:0JDI Sentiment 83%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.33%
12-Months-Change
Fundamentals
Return on Equity
-76.29%
Trailing 12-Months
Asset Growth
18.00%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
---
0JDI Company Deck
---
0JDI Earnings Call
Q4 2024
0:00 / 0:00
---
0JDI Revenue Breakdown
60.82% R&D
39.18% Commercial
---
0JDI Stock 12 Months Forecast
Average Price Target
$58.69
▲(39.31% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Illumina
―
Arrowhead Pharmaceuticals
―
Alnylam Pharma
―
Sarepta Therapeutics
―
Best Analysts Covering 0JDI
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+16.53%
initiated a buy rating 7 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +16.53% per trade.
---